These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25265401)

  • 1. Targeting matrix metalloproteinases: exploring the dynamics of the s1' pocket in the design of selective, small molecule inhibitors.
    Fabre B; Ramos A; de Pascual-Teresa B
    J Med Chem; 2014 Dec; 57(24):10205-19. PubMed ID: 25265401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Understanding the variability of the S1' pocket to improve matrix metalloproteinase inhibitor selectivity profiles.
    Gimeno A; Beltrán-Debón R; Mulero M; Pujadas G; Garcia-Vallvé S
    Drug Discov Today; 2020 Jan; 25(1):38-57. PubMed ID: 31513929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling.
    Park HI; Jin Y; Hurst DR; Monroe CA; Lee S; Schwartz MA; Sang QX
    J Biol Chem; 2003 Dec; 278(51):51646-53. PubMed ID: 14532275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery.
    Baidya SK; Banerjee S; Adhikari N; Jha T
    J Med Chem; 2022 Aug; 65(16):10709-10754. PubMed ID: 35969157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An integrated computational and experimental approach to gaining selectivity for MMP-2 within the gelatinase subfamily.
    Fabre B; Filipiak K; Díaz N; Zapico JM; Suárez D; Ramos A; de Pascual-Teresa B
    Chembiochem; 2014 Feb; 15(3):399-412. PubMed ID: 24449516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arylsulfonamides and selectivity of matrix metalloproteinase-2: An overview.
    Adhikari N; Mukherjee A; Saha A; Jha T
    Eur J Med Chem; 2017 Mar; 129():72-109. PubMed ID: 28219048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitory Antibodies Designed for Matrix Metalloproteinase Modulation.
    Fischer T; Riedl R
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31216704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third generation of matrix metalloprotease inhibitors: Gain in selectivity by targeting the depth of the S1' cavity.
    Devel L; Czarny B; Beau F; Georgiadis D; Stura E; Dive V
    Biochimie; 2010 Nov; 92(11):1501-8. PubMed ID: 20696203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors.
    Fischer T; Senn N; Riedl R
    Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specificity of binding with matrix metalloproteinases.
    Gupta SP; Patil VM
    Exp Suppl; 2012; 103():35-56. PubMed ID: 22642189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular dynamics simulations of metalloproteinases types 2 and 3 reveal differences in the dynamic behavior of the S1' binding pocket.
    de Oliveira CA; Zissen M; Mongon J; McCammon JA
    Curr Pharm Des; 2007; 13(34):3471-5. PubMed ID: 18220784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Probing the S1' site for the identification of non-zinc-binding MMP-2 inhibitors.
    Di Pizio A; Laghezza A; Tortorella P; Agamennone M
    ChemMedChem; 2013 Sep; 8(9):1475-82, 1421. PubMed ID: 23873724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quest for selectivity in inhibition of matrix metalloproteinases.
    Brown S; Meroueh SO; Fridman R; Mobashery S
    Curr Top Med Chem; 2004; 4(12):1227-38. PubMed ID: 15320723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
    Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
    Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting matrix metalloproteinases: design of a bifunctional inhibitor for presentation by tumour-associated galectins.
    Bartoloni M; Domínguez BE; Dragoni E; Richichi B; Fragai M; André S; Gabius HJ; Ardá A; Luchinat C; Jiménez-Barbero J; Nativi C
    Chemistry; 2013 Feb; 19(6):1896-902. PubMed ID: 23280962
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Dynamics Simulations of Matrix Metalloproteinase 13 and the Analysis of the Specificity Loop and the S1'-Site.
    Choi JY; Chung E
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibitors: a patent review (2011 - 2013).
    Li NG; Tang YP; Duan JA; Shi ZH
    Expert Opin Ther Pat; 2014 Sep; 24(9):1039-52. PubMed ID: 25098768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the binding of inhibitors of matrix metalloproteinases by molecular docking, quantum mechanical calculations, molecular dynamics simulations, and a MMGBSA/MMBappl study.
    Singh T; Adekoya OA; Jayaram B
    Mol Biosyst; 2015 Apr; 11(4):1041-51. PubMed ID: 25611160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the binding sites of matrix metalloproteinases and tumor necrosis factor-alpha converting enzyme: implications for selectivity.
    Lukacova V; Zhang Y; Kroll DM; Raha S; Comez D; Balaz S
    J Med Chem; 2005 Apr; 48(7):2361-70. PubMed ID: 15801829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural differences of matrix metalloproteinases with potential implications for inhibitor selectivity examined by the GRID/CPCA approach.
    Terp GE; Cruciani G; Christensen IT; Jørgensen FS
    J Med Chem; 2002 Jun; 45(13):2675-84. PubMed ID: 12061871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.